Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
46
BIXT Quote, Financials, Valuation and Earnings
Last price:
$0.0900
Seasonality move
:
36.73%
Day range:
$0.0706 - $0.0949
52-week range:
$0.0391 - $0.2283
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
35.48x
P/B ratio:
--
Volume:
803.9K
Avg. volume:
151.6K
1-year change:
-4.26%
Market cap:
$8.9M
Revenue:
--
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, BioXyTran, Inc. has -- downside to fair value with a price target of -- per share.
BIXT vs. S&P 500
-
Over the past 5 trading days, BioXyTran, Inc. has overperformed the S&P 500 by 27.16% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioXyTran, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioXyTran, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter BioXyTran, Inc. reported revenues of --.
Earnings Growth
-
BioXyTran, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioXyTran, Inc. reported earnings per share of -$0.00.
Enterprise value:
10.3M
EV / Invested capital:
--
Price / LTM sales:
35.48x
EV / EBIT:
--
EV / Revenue:
38.19x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-37.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$11.5K
Return On Assets:
-1432.48%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$8.1K | -$8.9K | -$11.5K | -$1.5K | -$4.2K | |
| Operating Income | -$3.6M | -$2.8M | -$2.1M | -$347.7K | -$500.2K | |
| EBITDA | -$3.6M | -$2.8M | -$2.1M | -$346.2K | -$496K | |
| Diluted EPS | -$0.03 | -$0.02 | -$0.02 | -$0.00 | -$0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $743.3K | $374.2K | $80.3K | $34.7K | $14.5K | |
| Total Assets | $762.2K | $448.5K | $189K | $159K | $156.3K | |
| Current Liabilities | $2.7M | $3M | $2.3M | $1.2M | $3.1M | |
| Total Liabilities | $2.7M | $3M | $2.3M | $1.2M | $3.1M | |
| Total Equity | -$1.9M | -$2.5M | -$2.1M | -$1.1M | -$2.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$837.4K | $745.4K | -$247.2K | $32K | -$33K | |
| Cash From Investing | -$39.8K | -$22.7K | -$27.2K | -$10.8K | -$1.7K | |
| Cash From Financing | $583.4K | -$768.3K | $254.2K | -- | $46K | |
| Free Cash Flow | -$877.3K | $722.7K | -$274.4K | $21.2K | -$34.7K | |
BIXT
Sector
Market Cap
$8.9M
$28.2M
Price % of 52-Week High
39.42%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-1.76%
-1.54%
1-Year Price Total Return
-4.26%
-18.1%
Beta (5-Year)
1.935
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.0738
200-day SMA
Sell
Level
$0.1032
Bollinger Bands (100)
Buy
Level
0.0637 - 0.0837
Chaikin Money Flow
Buy
Level
3.7M
20-day SMA
Buy
Level
$0.0745
Relative Strength Index (RSI14)
Buy
Level
66.1559
ADX Line
Buy
Level
15.5031
Williams %R
Sell
Level
-16.443
50-day SMA
Buy
Level
$0.0712
MACD (12, 26)
Buy
Level
0.0013
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-258.2862)
Sell
CA Score
(Annual)
Level (-145.7341)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (176.6658)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. Its product pipeline includes BXT-25, a drug designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke, and BXT-252, which treats chronic wounds resulting from ischemia caused by occlusion of capillaries. The company was founded on June 9, 2008 and is headquartered in Needham, MA.
Stock Forecast FAQ
In the current month, BIXT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIXT average analyst price target in the past 3 months is --.
-
Where Will BioXyTran, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioXyTran, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About BioXyTran, Inc.?
Analysts are divided on their view about BioXyTran, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioXyTran, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is BioXyTran, Inc.'s Price Target?
The price target for BioXyTran, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIXT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioXyTran, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BIXT?
You can purchase shares of BioXyTran, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioXyTran, Inc. shares.
-
What Is The BioXyTran, Inc. Share Price Today?
BioXyTran, Inc. was last trading at $0.0900 per share. This represents the most recent stock quote for BioXyTran, Inc.. Yesterday, BioXyTran, Inc. closed at $0.0900 per share.
-
How To Buy BioXyTran, Inc. Stock Online?
In order to purchase BioXyTran, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BIXT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIXT
Sector
P/E ratio
--
23.92x
PEG ratio
-0.10x
-0.01x
P/B ratio
--
1.83x
Price / LTM sales
35.48x
1.61x
Growth Metrics
BIXT
Sector
Revenue growth
--
4.6%
Earnings growth
-3.23%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.21
Profitability
BIXT
Sector
Profitability FY 2024
-$8K
$3.5M
Return on invested capital
--
-31.84%
Return on assets
-1432.48%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Dec
28
Next Earnings Date
Dec
28
Estimated Next Earnings Date
Mar
29
Balance Sheet
BIXT
Sector
Total cash
$14.5K
$26.3M
Short term investments
--
$25.7M
Total assets
$138.7K
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
